Optimization of an adult immunization program in Canada
Locke, N.; Paulden, M.; MacDonald, S. E.; Montesanti, S.; Tuite, A.; Hempel, K.; McDonald, W.; Rafferty, E.
Show abstract
BackgroundProvincial decisions to fund a new immunization program are generally made on a case-by-case basis, without systematic consideration of how the new immunization program may fit within the larger provincial immunization portfolio. AimThe goal of this study was to develop evidence and tools to guide policy-makers in making fiscally and ethically responsible decisions on which adult immunization programs to include in their portfolio under various constrained budgetary scenarios. MethodsUsing previously published infectious disease models, cost-utility data was estimated for adult pneumococcal, influenza, pertussis, and shingles immunization programs. This data was then inputted into a newly developed constrained optimization model to determine portfolios of immunization programs that maximize either population health or incremental net monetary benefit, subject to a budget constraint. Sensitivity analyses were conducted on model parameters such as vaccine costs, cost-effectiveness thresholds, and the budget constraint. ResultsOptimized solutions changed dramatically based on the number of immunization programs included, total budget, what was optimized for (i.e., population health or incremental net monetary benefit), the cost-effectiveness threshold and the assumed vaccine prices. Maximal health gains and budget spending was achieved when optimizing based on population health. Reductions in health gains and budget spending were observed at a CAN$50,000 cost-effectiveness threshold, and at a CAN$30,000 threshold, the budget was significantly underutilized and health gains were noticeably reduced. ConclusionIf budgets for the adult immunization portfolio are fixed, then shifting to more expensive programs that offer large health benefits may be preferable. However, if budgets can be spread across various public health programs (i.e., childhood immunization, well-baby programs), it may make more sense to optimize based on cost-effectiveness. Constrained optimization tools could improve goals-based decision-making and allow for transparent and effective methods to make allocation decisions. HighlightsO_LIOptimized solutions changed dramatically based on the number of immunization programs available, total budget, and the cost-effectiveness threshold. C_LIO_LIIf budgets for the adult immunization portfolio are fixed, then shifting to more expensive programs that offer large health benefits may be preferable. C_LIO_LIIf budgets can be spread across various public health programs, it may make more sense to optimize based on cost-effectiveness. C_LIO_LIConstrained optimization tools could improve goals-based decision-making and allow for transparent and effective methods to make allocation decisions. C_LI
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Modelling optimal vaccination strategies against Covid-19 in a context of Gamma variant predominance in Brazil 94%
- Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season 94%
- Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework 94%
Similar papers in this journal
- Cost-utility analysis of current COVID-19 vaccination program recommendations in Canada 95%
- Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: a modelling study 94%
- Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria 94%
Similar papers in this journal
Similar papers in this journal
- The Impact of Vaccination to Control COVID-19 Burden in the United States: A Simulation Modeling Approach 94%
- Evaluating respiratory syncytial virus immunization strategies for infants in Canada: a cost-utility analysis 93%
- A dynamic transmission model for assessing the impact of pneumococcal vaccination 93%
Similar papers in this journal
- Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany 92%
- Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 Vaccine in the United States 92%
- The Potential Clinical Impact of Implementing Different COVID-19 Boosters in Fall 2022 in the United States 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.